News from Industry out on PR Newswire amivantamab + lazertinib approved by U.S. FDA 🇺🇸 as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced #LungCancer 🫁 This approval follows the results of the Phase 3 MARIPOSA🦋 trial, where the combination

The #OncoAlert5k Barcelona🇪🇸 during #ESMO24 Runners Ready🎽 OncoAlert 🚨 #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Jose Fernando Moura, PhD Elisa Agostinetto Yakup Ergün Elisabetta Bonzano MD, PhD Bárbara Melão, MD Dr Joseph McCollom DO Erman Akkus Balazs Halmos

👇🏻👇🏻👇🏻

NIPPON (JCOG2007): Chemo + pembro vs chemo + nivo–ipi as 1st line Tx for #NSCLC. OncoAlert ❌ No difference in PFS/OS 🏥Terminated early due to safety issues (7% treatment-related deaths w/ nivo/ipi) ➡️ underpowered to derive a definitive conclusion and for robust key

The OncoAlert 🚨Newsletter (August 16-22, 2024) is out! This week covering: 🫁U.S. FDA 🇺🇸lazertinib+amivantamab #NSCLC & Efficacy of ICI in #EGFR mut NSCLC ☢️SABR for oligoprograssive Cancers ASTRO & more.. Register at Oncoalert360.com or

On behalf of International Urology Cancer Summit & the OncoAlert 🚨Network, extending a warm invitation to join us for the second International Urology Cancer Summit #IUCS24 HYBRID & FREE_‼️ September 27, 2024 in Portsmouth UK 🇬🇧 & ONLINE REGISTER: urologycancersummit.org/registration/

Cancer Survivors' Experience of Care and Financial Toxicity: Results From a National Survey This study examined the relationship between patient experience of care (PEC) and financial toxicity💰 (FT) among cancer survivors using data from the 2016-2017 Medical Expenditure Panel

Thoughtful The New York Times story on how to find a good oncologist. Here’s a shortcut: just call ⁦Dana-Farber⁩! nytimes.com/2024/08/22/wel… via @NYTimes

What is the current therapeutic landscape for #LungCancer with KRAS, HER2, and C-MET alterations? Explore the topic with Biagio Ricciuti, MD PhD at the upcoming #ILCS24, live in Lausanne or virtually! 🗓️ 4th Oct 2024, from 10AM CET Register and get involved in the discussion ⬇️

Barcelona 🇪🇸 #ESMO24 We Are There🚨 For Colleagues....By Colleagues #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Eric K. Singhi, MD Bárbara Melão, MD

The OncoAlert 🚨Newsletter NOW OUT Covering August 23-29, 2024 Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale…

The OncoAlert 🚨Newsletter Covering August 23-29, 2024 is out! Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… 📫📫📫 This week discussing: ✅ESMO Tumour-Agnostic Classifier and Screener ✅Next-generation #LungCancer 🫁 pathology🔬 ✅promises & challenges in

Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Elisa Agostinetto 🇮🇹 Elisabetta Bonzano MD, PhD 🇮🇹 Luca Arecco, MD 🇮🇹 Gil Morgan, MD 🇺🇸 With our distinguished OncoAlert Faculty: Sara Tolaney

Sustained clinical benefit & intracranial activity of Tarlatamab in previously treated #SCLC. 🚨OncoAlert DeLLphi-300 - Ph I 🏥ORR 25.0% (4 CR) w/mDoR of 11.2 mo ✅Intracranial ORR 62.5% (w/ prior RT) 📈mOS 17.5m #LCSM ascopubs.org/doi/10.1200/JC…

Really grateful to be part of this exciting and collaborative research on #KRAS G12C adaptive resistance and therapy ⁦AmbrogioLab⁩ ⁦Santamaria Lab⁩ ⁦Biagio Ricciuti, MD PhD⁩ 🚨🚨🚨 out on ⁦Nature Communications⁩ nature.com/articles/s4146…

🚨“Can’t-miss” lung cancer abstracts to be presented at #ESMO24! OncoAlert Hidehito HORINOUCHI Biagio Ricciuti, MD PhD Eric K. Singhi, MD Gil Morgan, MD

The OncoAlert 🚨Newsletter is out. August 30- Sept 5, 2024 Covering: DeLLphi-300🫁 SCLC #tarlatamab #LungCancer ; LITESPARK-013 #KidneyCancer & NeoAdj #Immunotherapy #BreastCancer among others! 👇🏻👇🏻👇🏻 Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale…